Focused On-demand Library for Translation initiation factor eIF-2B subunit epsilon

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q13144

UPID:

EI2BE_HUMAN

Alternative names:

eIF-2B GDP-GTP exchange factor subunit epsilon

Alternative UPACC:

Q13144; Q541Z1; Q96D04

Background:

The Translation initiation factor eIF-2B subunit epsilon, also known as eIF-2B GDP-GTP exchange factor subunit epsilon, plays a pivotal role in protein synthesis. It catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP, a critical step in the initiation of translation. This protein's function is essential for the regulation of protein synthesis, impacting cellular growth and response to stress.

Therapeutic significance:

Leukoencephalopathy with vanishing white matter 5, a devastating brain disease, is directly linked to mutations in the gene encoding this protein. The disease manifests with progressive cerebellar ataxia, spasticity, cognitive deficits, and in severe cases, ovarian dysfunction in females. Understanding the role of Translation initiation factor eIF-2B subunit epsilon could open doors to potential therapeutic strategies for this and related neurological disorders.